Changes

Jump to: navigation, search

Interferon For Treatment of Melanoma

6,584 bytes removed, 07:07, 7 September 2018
==Dashboard==
* Click here to view '''[http://clientwww.dolcera.com/auth/dashboard/dashboard.htmlphp?workfile_id=890 891 Sample Dashboard]'''
NOTE: You need to install Internet Explorer 8.0 and Adobe Flash Player to view the Dashboard.
==Concept Table==
{|border="2" cellspacing="0" cellpadding="4" width="50100%"
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center>
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center>
|}
===French Keywords Concept table===
{|border="2" cellspacing="0" cellpadding="4" width="50100%"
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center>
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center>
===German Keywords Concept Table===
{|border="2" cellspacing="0" cellpadding="4" width="50100%"
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''S.No'''</center>
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''Concept-1'''</center>
* '''Relevant IPC classes'''
{|border="2" cellspacing="0" cellpadding="4" width="75100%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''IPC'''
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''Sr. No.'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class Code'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class definition'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing peptides Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''3'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''4'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''5'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''6'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''7'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''8'''
|align = "center"|A61P003500
|align = "center"|Therapeutic activity of chemical compounds or medicinal preparations -antineoplastic agents
* '''Relevant ECLA classes'''
{|border="2" cellspacing="0" cellpadding="4" width="75100%"
|align = "center" bgcolor = "#99CCFF" colspan = "4"|'''ECLA'''
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''Sr. No.'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class Code'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class definition'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class coverage'''
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''1'''
|align = "center"|A61K003819
|align = "center"|Medicinal preparations containing peptides - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''2'''
|align = "center"|A61K003821
|align = "center"|Medicinal preparations containing Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''3'''
|align = "center"|A61K38/21A
|align = "center"|Medicinal preparations containing IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''4'''
|align = "center"|A61K38/21B
|align = "center"|Medicinal preparations containing IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''5'''
|align = "center"|A61K38/21C
|align = "center"|Medicinal preparations containing IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''6'''
|align = "center"|C07K001452
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof - Cytokines; Lymphokines; Interferons
|align = "center"|Broad
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''7'''
|align = "center"|C07K014555
|align = "center"|Peptides having more than 20 amino acids - Interferon
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''8'''
|align = "center"|C07K001456
|align = "center"|Peptides having more than 20 amino acids - IFN-alpha
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''9'''
|align = "center"|C07K014565
|align = "center"|Peptides having more than 20 amino acids - IFN-beta
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''10'''
|align = "center"|C07K001457
|align = "center"|Peptides having more than 20 amino acids - IFN-gamma
|align = "center"|Specific
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''11'''
|align = "center"|C07K014715G
|align = "center"|Receptors; Cell surface antigens; Cell surface determinants - for interferons -
* '''Relevant US classes'''
{|border="2" cellspacing="0" cellpadding="4" width="50100%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''US class'''
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''Sr. No.'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class Code'''|align = "center" bgcolor = "#C0C0C099ccff"|'''Class definition'''
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''1'''
|align = "center"|4240854
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - this subclass provides for patents which broadly claim interferon or a method of treatment of interferon where the classification of the interferon as alpha, beta or gamma interferon is impossible
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''2'''
|align = "center"|4242811
|align = "center"| DRUG, BIO-AFFCTING AND BODY TREATING COMPOSITIONS - Virus (e.g., interferon-inducing virus, etc.)
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''3'''
|align = "center"|42400141
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - Attached to lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, or intercellular mediator specific for a hematopoietic cell (e.g., interferon, interleukin, macrophage factor, colony stimulating factor, erythropoietin); derivative thereof
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''4'''
|align = "center"|514889
|align = "center"|DRUG, BIO-AFFECTING AND BODY TREATING COMPOSITIONS - INTERFERON INDUCER
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''5'''
|align = "center"|530351
|align = "center"| CHEMISTRY: NATURAL RESINS OR DERIVATIVES; PEPTIDES OR PROTEINS; LIGNINS OR REACTION PRODUCTS THEREOF - Lymphokines, e.g., interferons, interlukins, etc.
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''6'''
|align = "center"|930142
|align = "center"|PEPTIDE OR PROTEIN SEQUENCE - Interferon
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''7'''
|align = "center"|4240851
|align = "center"|LYMPHOKINE - Included in this and the indented subclasses interferon, interleukin and macrophage factors (monokines)
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''8'''
|align = "center"|4240855
|align = "center"|Gamma or immune: This subclass is indented under subclass 85.4. Subject matter in which the interferon is gamma or immune interferon.
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''9'''
|align = "center"|4240856
|align = "center"|Subject matter in which the interferon is beta or fibroblast interferon.
|-
|align = "center" bgcolor = "#C0C0C099ccff"|'''10'''
|align = "center"|4240857
|align = "center"|Subject matter in which the interferon is alpha or leukocyte interferon.
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''SrS. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|576
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title, Abstract and Claims
|align = "center"|756
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''3'''
|align = "center"|'''Final query'''
|align = "center" colspan = "4"|'''1 OR 2'''
{|border="2" cellspacing="0" cellpadding="4" align = "center" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''SrS. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Language'''
|-
|}
 
===Search in Micropatent MPI-INPADOC - English language search===
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''SrS. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Search Scope'''
|align = "center" bgcolor = "#99CCFF"|'''No. of hits'''
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''1'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|174
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''2'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|484
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''3'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|102
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''4'''
|align = "center"|Interferon for treating Melanoma
|align = "center"|Title and Abstract
|align = "center"|9
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''5'''
|align = "center" colspan = "4"|'''Final query'''
|align = "center"|'''1 OR 2 OR 3 OR 4'''
{|border="2" cellspacing="0" cellpadding="4" width="100%"
|align = "center" bgcolor = "#99CCFF"|'''SrS. No.'''
|align = "center" bgcolor = "#99CCFF"|'''Search concept'''
|align = "center" bgcolor = "#99CCFF"|'''Language'''
Date of search: 1900/01/01 to 2011/02/15
{| border="2" cellspacing="0" cellpadding="4" align = "left" width="50100%"
| style="background-color:#99ccff;padding:0.079cm;"| '''S.No.'''
| style="background-color:#99ccff;padding:0.079cm;"| <center>'''Issue/Publication date'''</center>
* '''F-Terms and theme used in search'''
{|border="2" cellspacing="0" cellpadding="4" width="75100%"
|align = "center" bgcolor = "#99CCFF" colspan = "3"|'''Japanese F-term search'''
|align = "center" bgcolor = "#99CCFF"|'''Definition'''
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''Sr. No.'''
|align = "center"|'''F- Term theme'''
|align = "center"|'''4H045'''
|align = "center"|Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''1'''
|align = "center"|F-term
|align = "center"|DA15
|align = "center"|Peptide or protein characterised by function - Interferons
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''2'''
|align = "center"|F-term
|align = "center"|DA16
|align = "center"|Alpha-interferons
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''3'''
|align = "center"|F-term
|align = "center"|DA17
|align = "center"|Beta-interferons
|-
|align = "center" bgcolor = "#C0C0C099CCFF"|'''4'''
|align = "center"|F-term
|align = "center"|DA18
===Scientific Literature Search===
{|border="2" cellspacing="0" cellpadding="4" width="50100%"| style="background-color:#99ccff;padding:0.079cm;"| <center><b>S.No</b></center>| style="background-color:#99ccff;padding:0.079cm;"| <center><b>Database</b></center>| style="background-color:#99ccff;padding:0.079cm;"| <center><b>Query</b></center>| style="background-color:#99ccff;padding:0.079cm;"| <center><b>Limits by Date</b></center>| style="background-color:#99ccff;padding:0.079cm;"| <center><b>No.Of Hits</b></center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>1</b></center>
| style="padding:0.079cm;"| <center>Pubmed</center>
| style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>2</b></center>
| style="padding:0.079cm;"| <center>Scirus</center>
| style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>3</b></center>
| style="padding:0.079cm;"| <center>Google Scholar</center>
| style="padding:0.079cm;"| <center>(Melanoma Or carcinoma or cancer* or tumor) And (IFN* OR Interferon)</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''1'''</center>
| style=";padding:0.079cm;"| <center>US7482014B2[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=7482014.PN.&OS=PN/7482014&RS=PN/7482014US7482014B2]</center>
| style=";padding:0.079cm;"| <center>01/27/2009</center>
| style=";padding:0.079cm;"| <center>Schering Corporation</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''2'''</center>
| style=";padding:0.079cm;"| <center>US5997858A[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5997858.PN.&OS=PN/5997858&RS=PN/5997858US5997858A]</center>
| style=";padding:0.079cm;"| <center>12/7/1999</center>
| style=";padding:0.079cm;"| <center>Pharma Pacific Pty Ltd.</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''3'''</center>
| style=";padding:0.079cm;"| <center>[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19881026&CC=EP&NR=0288055A1&KC=A1 EP288055A1]</center>
| style=";padding:0.079cm;"| <center>10/26/1988</center>
| style=";padding:0.079cm;"| <center>MERRELL DOW PHARMACEUTICALS INC.</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''4'''</center>
| style=";padding:0.079cm;"| <center>[http://v3.espacenet.com/publicationDetails/biblio?DB=EPODOC&adjacent=true&locale=en_EP&FT=D&date=19871014&CC=EP&NR=0241242A1&KC=A1 EP241242A1]</center>
| style=";padding:0.079cm;"| <center>10/14/1987</center>
| style=";padding:0.079cm;"| <center>CETUS ONCOLOGY CORPORATION</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''5'''</center>
| style=";padding:0.079cm;"| <center>US20100086518[http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220100086518%22.PGNR.&OS=DN/20100086518&RS=DN/20100086518US20100086518] </center>
| style=";padding:0.079cm;"| <center>4/8/2010</center>
| style=";padding:0.079cm;"| <center>NOVARTIS AG</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''6'''</center>
| style=";padding:0.079cm;"| <center>US4846782[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4846782.PN.&OS=PN/4846782&RS=PN/4846782US4846782] </center>
| style=";padding:0.079cm;"| <center>7/11/1989</center>
| style=";padding:0.079cm;"| <center>Schering Corporation</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''7'''</center>
| style=";padding:0.079cm;"| <center>US5824300[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5824300.PN.&OS=PN/5824300&RS=PN/5824300US5824300] </center>
| style=";padding:0.079cm;"| <center>10/20/1998</center>
| style=";padding:0.079cm;"| <center>The Texas A&M University System</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''8'''</center>
| style=";padding:0.079cm;"| <center>US20020107184[http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220020107184%22.PGNR.&OS=DN/20020107184&RS=DN/20020107184US20020107184]</center>
| style=";padding:0.079cm;"| <center>8/8/2002</center>
| style=";padding:0.079cm;"| <center>None</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''9'''</center>
| style=";padding:0.079cm;"| <center>US4762705[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=4762705.PN.&OS=PN/4762705&RS=PN/4762705US4762705] </center>
| style=";padding:0.079cm;"| <center>8/9/1988</center>
| style=";padding:0.079cm;"| <center>Schwimmer, Adolf W. | Schwartz, Irwin Steven | Rubin, David</center>
|-
| style="background-color:#99ccff;;padding:0.079cm;"| <center>'''10'''</center>
| style=";padding:0.079cm;"| <center>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5190751.PN.&OS=PN/5190751&RS=PN/5190751 US5190751 ] </center>
| style=";padding:0.079cm;"| <center>3/2/1993</center>
| style=";padding:0.079cm;"| <center>Schering Corporation</center>
4 : Published Patent & Focus in Dependent claim <br>
{|border="2" cellspacing="0" cellpadding="4" width="50100%"| style="background-color:#99ccff;padding:0.079cm;"| <center><b>S.No</b></center>| style="background-color:#99ccff;padding:0.079cm;"| <center><b>Patent</b></center>| style="background-color:#99ccff;padding:0.079cm;"| <center><b>Type</b></center>| style="background-color:#99ccff;padding:0.079cm;"| <center><b>Patent Ranking</b></center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>1</b></center>
| style="padding:0.079cm;"| <center>US7482014B2</center>
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>2</b></center>
| style="padding:0.079cm;"| <center>US5997858A</center>
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>3</b></center>
| style="padding:0.079cm;"| <center>EP288055A1</center>
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>4</b></center>
| style="padding:0.079cm;"| <center>EP241242A1</center>
| style="padding:0.079cm;"| <center>Granted And Dependent Claim</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>5</b></center>
| style="padding:0.079cm;"| <center>US20100086518 </center>
| style="padding:0.079cm;"| <center>Published And Dependent</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>6</b></center>
| style="padding:0.079cm;"| <center>US4846782 </center>
| style="padding:0.079cm;"| <center>Granted And Dependent Claim</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>7</b></center>
| style="padding:0.079cm;"| <center>US5824300 </center>
| style="padding:0.079cm;"| <center>Granted And Dependent Claim</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>8</b></center>
| style="padding:0.079cm;"| <center>US20020107184</center>
| style="padding:0.079cm;"| <center>Published And Independent</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>9</b></center>
| style="padding:0.079cm;"| <center>US4762705 </center>
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center>
|-
| style="background-color:#99ccff;padding:0.079cm;"| <center><b>10</b></center>
| style="padding:0.079cm;"| <center>US5190751 </center>
| style="padding:0.079cm;"| <center>Granted And Independent Claim</center>
===Global Revenue Data Of products===
  <table cellpadding{|border="32" cellspacing="0"> <tr> <td colspancellpadding="14" rowspanwidth="2" style="background: none repeat scroll 0100% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thick solid rgb(0, 0, 0); border-left: thick solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valignrowspan ="center2"><strong>|'''S.No</strong></td>''' <td colspan="1" rowspan="2" style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valignrowspan ="center2"><strong>|''' Generic Name</strong></td>''' <td colspan="1" rowspan="2" style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valignrowspan ="center2"><strong>|''' Brand Name</strong></td>''' <td colspan="1" rowspan="2" style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valignrowspan ="center2"><strong>|''' Company</strong></td>''' <td colspan="3" rowspan="1" style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valigncolspan ="center3"><strong>|''' Global revenue ($ Million )</strong></td>''' </tr>|- <tr> <td style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="centerright" bgcolor="#99ccffC5D9F1" valign="center"><strong>|'''2008</strong></td>''' <td style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="centerright" bgcolor="#99ccffC5D9F1" valign="center"><strong>|'''2009</strong></td>''' <td style|align ="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-right: thick solid rgb(0, 0, 0);" align="center" bgcolor="#99ccffC5D9F1" valign="center"><strong>|'''2010</strong></td>''' </tr>|- <tr> <td style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thick solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valign="center"><strong>|'''1</strong></td>''' <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Alpha IFN</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Intron®,Roferon®-A</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">|Schering Corporation</td> <td style|align ="border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);right"></td>| <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="center" valign="bottomright">| 38.4</td>2 <td style|align ="border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-right: thick solid rgb(0, 0, 0);"></td>| </tr>|- <tr> <td style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thick solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valign="center"><strong>|'''2</strong></td>''' <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Beta IFN</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Avonex</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center"> |Biogen IDEC</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="centerright" valign="center">|2518.4</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="centerright" valign="center">|2322.9</td> <td style|align ="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-right: thick solid rgb(0, 0, 0);" align="center" valign="center">| 2202.6</td>3 </tr>|- <tr> <td style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thick solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valign="center"><strong>|'''3</strong></td>''' <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Gamma IFN</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Actimmune®</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Intermune</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="centerright" valign="center">|29880</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="center" valign="centerright">| 25428</td>4 <td style|align ="border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-right: thick solid rgb(0, 0, 0);"></td>| </tr>|- <tr> <td style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thick solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valign="center"><strong>|'''4</strong></td>''' <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Pegylated IFN</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Peg Intron</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center"> | Schering-Plough</td> <td style|align ="border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);right"></td>| <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="centerright" valign="center">| 148.7</td>5 <td style|align ="border-top: thin solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0); border-right: thick solid rgb(0, 0, 0);"></td>| </tr>|- <tr> <td style="background: none repeat scroll 0% 0% rgb(153, 204, 255); font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-bottom: thick solid rgb(0, 0, 0); border-left: thick solid rgb(0, 0, 0);" align="center" |bgcolor="#99ccff" valign="center"><strong>|'''5</strong></td>''' <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-bottom: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Recombinant IFN</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-bottom: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">(|Rebetron®, Rebetol®).</td> <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-bottom: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" align="center" valign="center">| Schering Corporation</td> <td style|align ="border-top: thin solid rgb(0, 0, 0); border-bottom: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);right"></td>| <td style="font-size: 10pt; border-top: thin solid rgb(0, 0, 0); border-bottom: thick solid rgb(0, 0, 0); border-left: thin solid rgb(0, 0, 0);" |align="center" valign="centerright">|36.1</td> <td style|align ="border-width: thin thick thick thin; border-style: solid; border-color: rgb(0, 0, 0);right"></td>| </tr> |- </table>|}
==Biosimilars Of Interferons==
349
edits